Sinovac Research And Development Co., Ltd.

This study tested a new vaccine (PCV13) designed to protect children from serious infections caused by pneumococcal bacteria, such as pneumonia and meningitis. The trial involved 140 healthy infants (2 months old) and children (2–5 years old) to check the vaccine's safety and how…